BioSpace News Archive

Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced it will present new clinical data on its personalized and tumor-informed molecular residual disease (MRD) assay, Signatera, at the 2021 American Society of Clinical Oncology (ASCO) annual meeting, taking place June 4-8, 2021 .

AIM ImmunoTech Inc. (NYSE American: AIM) today announced that it has completed dosing of Cohort 3 in a Phase 1 clinical study to assess the safety, tolerability and biological activity of Ampligen as an intranasal therapy, reporting no serious adverse events. This is consistent with results in the first two cohorts of the study and at escalating doses.

tDCS Treatments Improve Symptoms Related to Conditions like Multiple Sclerosis, COVID-19 & Other Neuropsychiatric Problems

Mirum Pharmaceuticals to Present Maralixibat Data and Host Symposium at the 6 th World Congress of Pediatric Gastroenterology, Hepatology and Nutrition (WCPGHAN) Annual Meeting 2021 - Integrated safety analysis on gastrointestinal tolerability of maralixibat in patients with Alagille syndrome presented in poster session.

Modern Vascular, a pioneering medical group dedicated to preventing amputation through the treatment of Peripheral Artery Disease, announced the opening of its first Wound Care Clinic in Southaven, Mississippi.

Research Highlights: - OneR Research Takes Center Stage with myTACTIC Trial Abstract - OneOncology Study Examining Clinical Trial Impact on Medicare’s Oncology Care Model Elevated to Poster Discussion - West Cancer Center Investigator to Present Phase 1 Study Results Examining Patients with Solid Malignancies in an Oral Abstract

Today, NRx Pharmaceuticals, Inc., (Nasdaq:NRXP) (NRx) through its Georgia subsidiary, announced that it has signed a master services agreement with Cromos Pharma, LLC, headquartered in Longview, Washington, to conduct phase 3 clinical trials of COVID-19 related drugs and vaccines in Central Europe and the Caucasus Region.

Novome Biotechnologies, Inc., a biotechnology company engineering first-in-class, living medicines for chronic diseases, today announced the appointments of David N. Cook, PhD, and Zachary Hornby, both accomplished biotechnology executives, to the Company’s Board of Directors.

PatientPoint® and the Lupus Foundation of America announced a new initiative that will bring lupus education and support resources to the offices of nearly 7,000 primary care physicians and rheumatologists nationwide.

For the first time in Midwest Orthopaedics at Rush history, one of its sports medicine physicians has been awarded a National Institute of Health grant as a Principal Investigator.